Quick Answer
RenovoRx, Inc. reported Operating Income Loss of -$12.51 million for the year ending 2025.
- RenovoRx, Inc. showed a decrease of -14.0% in Operating Income Loss from 2024 to 2025.
- This data is from RenovoRx, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), RenovoRx, Inc.'s Operating Income Loss has declined by 290.4%.
- Historical annual values: Fiscal year 2025: -$12.51 million | Fiscal year 2024: -$10.97 million | Fiscal year 2023: -$11.40 million | Fiscal year 2022: -$9.95 million | Fiscal year 2021: -$5.67 million | Fiscal year 2020: -$3.20 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: